📰 Planegg News
Page 28 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
May 11, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 M...
May 3, 2023
Monjuvi U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline
May 3, 2023
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2023 Financial Results ...
May 3, 2023
03.05.2023 - EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2023 Financial Results 03.05.2023 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release ...
April 27, 2023
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference ...
April 27, 2023
Conference Call AlertMUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST
April 27, 2023
EQS-News: MorphoSys AG / Key word: Quarter Results Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023 27.04.2023 / 22:03... | June 18, 2023
April 24, 2023
Electrochaea is expanding its presence in Planegg near Munich to accommodate its growth in engineering and commercial development. There is increasing demand for alternatives to fossil natural gas ...
April 17, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this...
April 16, 2023
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL... | April 16, 2023